EUVIMEDEUVIMED entdecken
Open Access

Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice

Huaqiang Bi, Jun Pei, Kuansheng Ma, Yanling Zhang, Giuseppe Aprile, Dimitrios Moris, Nahum Méndez-Sánchez, Hrishikesh Samant, Ximin Sun, Feng Xia

Journal of Gastrointestinal Oncology · 2024-02 · 15 (1) · 368-376

DOI: 10.21037/jgo-23-618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2024-02. Verfasst von Huaqiang Bi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Hepatocellular carcinoma (HCC)anti-program death-1 inhibitorsimmunotherapyobjective response rate (ORR)progression-free survival (PFS)

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
  • Department of Oncology, First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China.
  • Department of Medical Oncology, San Bortolo General Hospital, Vicenza, Italy.
  • Department of Surgery, Duke University Medical Center, Durham, NC, USA.
  • Liver Research Unit, Medica Sur Clinic and Foundation and Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
  • Division of Gastroenterology and Hepatology, LSU Health Science Center, Shreveport, LA, USA.

Zitieren

APA

Bi, H., Pei, J., Ma, K., Zhang, Y., Aprile, G., Moris, D., Méndez-Sánchez, N., Samant, H., Sun, X., & Xia, F. (2024). Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice. Journal of Gastrointestinal Oncology, 15(1), 368-376. https://doi.org/10.21037/jgo-23-618

Vancouver

Bi H, Pei J, Ma K, Zhang Y, Aprile G, Moris D, et al. Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice. Journal of Gastrointestinal Oncology. 2024;15(1):368-376. doi:10.21037/jgo-23-618

BibTeX
@article{Bi2024,
  author = {Bi, Huaqiang and Pei, Jun and Ma, Kuansheng and Zhang, Yanling and Aprile, Giuseppe and Moris, Dimitrios and Méndez-Sánchez, Nahum and Samant, Hrishikesh and Sun, Ximin and Xia, Feng},
  title = {Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2024},
  volume = {15},
  number = {1},
  pages = {368--376},
  doi = {10.21037/jgo-23-618}
}
Kostenlos starten →